6 completed. 4 Phase 1, 3 Phase 2, 1 Phase 3.
By phase and status
Follow ELPIDA®: new trials by email Literature Review of ELPIDA® trials Research Report on ELPIDA®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA®
VM-1500A-LAI, ELPIDA® - HIV-1-infection | Phase 1 / Phase 2 | Completed | 36 | 2021-01-19 | 2022-01-11 |
Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs
Elpida®, Rifampin, Rifabutin - HIV-1-infection | Phase 1 | Completed | 56 | 2018-11-14 | 2022-01-26 |
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Dasatinib - Chronic Myelogenous Leukemia | Phase 2 | Completed | 56 | 2018-11-05 | 2023-09-22 |
Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs
Elpida®, Dolutegravir, Sofosbuvir - HIV-1-infection, Hepatic Impairment | Phase 1 | Completed | 36 | 2018-10-01 | 2022-01-11 |
Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects
VM-1500FDC, Elpida®, Truvada® - HIV-1-infection | Phase 1 | Completed | 140 | 2018-06-01 | 2018-10-30 |
Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy
VM-1500, Efavirenz, Antiretroviral therapy (ART) - HIV-1-infection | Phase 2 / Phase 3 | Completed | 150 | 2014-08-05 | 2018-09-25 |
Conditions studied
Acquired Immunodeficiency Syndrome (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Chronic-Phase (1)
Sponsors
Viriom (5) · Hikma Pharmaceuticals LLC (1)
Countries
Russia (5) · Jordan (1) · Lebanon (1) · Saudi Arabia (1) · Tunisia (1)
Top investigators
Alla Andreeva, PhD (2) · Anastasia Pokrovskaya, PhD (1) · Elena Mazygula, PhD (1) · Elena Smolyarchuk, PhD (1) · Irina Y Tyrnova (1)